Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sanofi
With
Breast Cancer Research Foundation
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
invasive breast cancer
stage I-IIIA disease
ER, PR, Her2/neu-negative status
no prior treatment for breast cancer
age 18 years of greater
normal renal, liver function
normal hematologic status
ECOG Performance status 0, 1
Evaluation by a surgeon to determine breast conservation eligibility
Women of childbearing potential must have a documented negative pregnancy test within 2 months of study trial entry and agree to birth control during the duration of the trial therapy
Ability to understand and the willingness to sign a written informed consent document
You may not be if
Metastatic breast cancer
Inoperable breast cancer, including Stage IIIB and IIIC
Tumor size less than 1 centimeter
Prior surgery, systemic therapy, or radiotherapy for the current cancer
Hormone receptor-positive breast cancer
Her2/neu-positive breast cancer
Any concurrent condition which in the investigator's opinion makes it inappropriate for the patient to participate in the trial or which would jeopardize compliance with the protocol
Pregnant or nursing women
Receipt of any investigational agents within 30 days prior to commencing study treatment
Clareo Health | A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer
